Filing Flows › Comparisons › AUPH vs FHTX
Aurinia Pharmaceuticals vs Foghorn Therapeutics: AUPH and FHTX compared
Aurinia Pharmaceuticals is the larger company: $83.7M of revenue in its latest quarter (Q3 2026) against $83.5M for Foghorn Therapeutics (Q3 2026). Foghorn Therapeutics is growing faster (+925% against +14% a year earlier). Foghorn Therapeutics is more profitable, with an operating margin of 67.8% against 42.3%.
Where the money goes: AUPH and FHTX
Aurinia Pharmaceuticals (AUPH) · Q3 2026
Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart follows the revenue to costs, profit and cash.
Foghorn Therapeutics (FHTX) · Q3 2026
Foghorn Therapeutics, Q3 2026: revenue $83.5M (+925% year over year), operating margin 67.8%, net earnings $58.1M, operating cash flow −$18.2M. The chart follows the revenue to costs, profit and cash.
| Aurinia Pharmaceuticals (AUPH) | Foghorn Therapeutics (FHTX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $83.7M | $83.5M |
| Revenue growth, Y/Y | +14% | +925% |
| Operating margin | 42.3% | 67.8% |
| Net earnings | $31.7M | $58.1M |
| Net margin | 37.9% | 69.6% |
| Operating cash flow | $46.4M | −$18.2M |
| Market value | $2.2B | $132M |
| P/E | 7.2× | — |
| Analysts’ mean target | $18.29 | $4.17 |
Where the revenue comes from
Aurinia Pharmaceuticals
- Net product sales: $79.4M (95%)
- License, collaboration and royalty revenue: $4.3M (5%)
Questions
Which is bigger, Aurinia Pharmaceuticals or Foghorn Therapeutics?
Aurinia Pharmaceuticals is the larger company: $83.7M of revenue in its latest quarter (Q3 2026) against $83.5M for Foghorn Therapeutics (Q3 2026).
Is Aurinia Pharmaceuticals or Foghorn Therapeutics growing faster?
Foghorn Therapeutics is growing faster (+925% against +14% a year earlier).
Which is more profitable, Aurinia Pharmaceuticals or Foghorn Therapeutics?
Foghorn Therapeutics is more profitable, with an operating margin of 67.8% against 42.3%.
More: Aurinia Pharmaceuticals earnings · how Aurinia Pharmaceuticals makes money · Foghorn Therapeutics earnings · how Foghorn Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.